PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY

PureTech Health plc

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$1.48+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Apr 29, 2026	Before market open	–	–	–
Q4 FY2024 Ended Dec 31, 2024	Apr 30, 2025	Before market open	–	–	–
Q2 FY2024 Ended Jun 30, 2024	Aug 28, 2024	Before market open	–	–	–
Q4 FY2023 Ended Dec 31, 2023	Apr 25, 2024	Before market open	–	–	–
Q4 FY2022 Ended Dec 31, 2022	Apr 28, 2023	Before market open	–	–	–

Press releases

Announcements PureTech Health filed with the SEC

May 1, 2026, 8:05 AM ET
PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
EX-99.1 to Form 6-K
Apr 29, 2026, 6:08 AM ET
PureTech Announces Annual Results for Year Ended December 31, 2025
EX-99.1 to Form 6-K
Apr 29, 2026, 6:05 AM ET
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London
EX-99.1 to Form 6-K
Dec 18, 2025, 7:00 AM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
EX-99.1 to Form 6-K
Dec 10, 2025, 4:30 PM ET
Results of Annual General Meeting on June 16, 2025 – Update Statement
EX-99.1 to Form 6-K
Aug 28, 2025, 6:47 AM ET
PureTech Health plc – Half-Year Report
EX-99.1 to Form 6-K
Aug 28, 2025, 6:47 AM ET
Interim Management Report and Financial Review
EX-99.2 to Form 6-K
Aug 28, 2025, 6:47 AM ET
Condensed Consolidated Statement of Comprehensive Income/(Loss) (Unaudited)
EX-99.3 to Form 6-K
Jul 16, 2025, 6:30 AM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
EX-99.1 to Form 6-K
Jul 8, 2025, 4:15 PM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
EX-99.1 to Form 6-K
Jun 16, 2025, 4:30 PM ET
Results of Annual General Meeting
EX-99.1 to Form 6-K
Apr 30, 2025, 6:30 AM ET
PureTech Announces Annual Results for Year Ended December 31, 2024
EX-99.1 to Form 6-K
Apr 7, 2025, 4:15 PM ET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
EX-99.1 to Form 6-K
Dec 16, 2024, 8:05 AM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART
EX-99.1 to Form 6-K
Oct 21, 2024, 4:30 PM ET
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
EX-99.1 to Form 6-K
Sep 27, 2024, 4:30 PM ET
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of
EX-99.1 to Form 6-K
Aug 28, 2024, 4:31 PM ET
Results of Annual General Meeting on 13 June 2024 Update Statement
EX-99.1 to Form 6-K
Aug 28, 2024, 7:29 AM ET
PureTech Health plc – Half-Year Report
EX-99.1 to Form 6-K
Aug 28, 2024, 7:29 AM ET
Interim Management Report and Financial Review
EX-99.2 to Form 6-K
Aug 28, 2024, 7:29 AM ET
Condensed Consolidated Statement of Comprehensive Income/(Loss) (Unaudited)
EX-99.3 to Form 6-K
Aug 22, 2024, 4:30 PM ET
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
EX-99.1 to Form 6-K
Jun 24, 2024, 4:35 PM ET
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO
EX-99.1 to Form 6-K
Jun 24, 2024, 4:35 PM ET
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO
EX-99.2 to Form 6-K
Jun 20, 2024, 7:30 AM ET
PureTech Announces Change of Board Role
EX-99.1 to Form 6-K
Jun 13, 2024, 4:30 PM ET
Results of Annual General Meeting
EX-99.1 to Form 6-K
Jun 6, 2024, 4:30 PM ET
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics
EX-99.1 to Form 6-K
Jun 4, 2024, 4:30 PM ET
Proposed $100 million Tender Offer at 250 pence per Ordinary Share
EX-99.1 to Form 6-K
May 29, 2024, 4:33 PM ET
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading
EX-99.1 to Form 6-K
May 20, 2024, 4:30 PM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS
EX-99.1 to Form 6-K
Apr 25, 2024, 6:30 AM ET
PureTech Announces Annual Results for Year Ended December 31, 2023
EX-99.1 to Form 6-K
Apr 9, 2024, 6:30 AM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS
EX-99.1 to Form 6-K
Mar 19, 2024, 8:30 AM ET
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014)
EX-99.1 to Form 6-K
Mar 18, 2024, 4:30 PM ET
Bristol Myers Squibb Completes Acquisition of PureTechs Founded Entity Karuna Therapeutics for $14 Billion
EX-99.1 to Form 6-K
Dec 20, 2023, 6:30 AM ET
PureTech Year End Update and Outlook for 2024
EX-99.1 to Form 6-K
Aug 29, 2023, 6:33 AM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Jun 14, 2023, 4:32 PM ET
Results of Annual General Meeting
EX-99.1 to Form 6-K
Jun 12, 2023, 4:30 PM ET
This letter is being sent to the shareholders of PureTech Health plc (the ‘Company’) for information only and no
EX-99.1 to Form 6-K
Jun 12, 2023, 4:30 PM ET
Statement to PureTech Health plc (no. 09582467) on ceasing to hold office as auditors pursuant to section 519 of the Companies Act 2006
EX-99.2 to Form 6-K
Apr 28, 2023, 6:07 AM ET
PureTech Announces Annual Results for Year Ended December 31, 2022
EX-99.1 to Form 6-K
Mar 23, 2023, 6:30 AM ET
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in PureTech Health's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PTCHF.

Revenue growth-3.5% · median 74.2%

Operating margin-2114.8% · median -665.2%

Net margin-2355.4% · median -618.0%

Company	Revenue	Growth
JAGX	$27.82M	+135.5%
ROIV	$7.53M	-67.6%
RANI	$4.88M	+306.4%
BOLT	$4.70M	+12.8%
PTCHF	$4.66M	-3.5%
IMMP	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1782999

Advertisement
300 × 250